ArticleJournal of cheminformatics2018
A neural network approach to chemical and gene/protein entity recognition in patents.
Article in Journal of cheminformatics, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- DeIDNER Model: A Neural Network Named Entity Recognition Model for Use in the De-identification of Clinical Notes.Biomedical engineering systems and technologies, international joint conference, BIOSTEC ... revised selected papers. BIOSTEC (Conference) · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
In biomedical research, patents contain the significant amount of information, and biomedical text mining has received much attention in patents recently. To accelerate the development of biomedical text mining for patents, the BioCreative V.5 challenge organized three tracks, i.e., chemical entity mention recognition (CEMP), gene and protein related object recognition (GPRO) and technical interoperability and performance of annotation servers, to focus on biomedical entity recognition in patents. This paper describes our neural network approach for the CEMP and GPRO tracks. In the approach, a bidirectional long short-term memory with a conditional random field layer is employed to recognize biomedical entities from patents. To improve the performance, we explored the effect of additional features (i.e., part of speech, chunking and named entity recognition features generated by the GENIA tagger) for the neural network model. In the official results, our best runs achieve the highest performances (a precision of 88.32%, a recall of 92.62%, and an F-score of 90.42% in the CEMP track; a precision of 76.65%, a recall of 81.91%, and an F-score of 79.19% in the GPRO track) among all participating teams in both tracks.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.